A total of 2306 patients were enrolled in the initial open-label phase of the study. Of these, 627 patients who showed a suboptimal response after 8 weeks of treatment with olmesartan medoxomil 20 ...

Median time to remission was 24 weeks and median dose in remission was 30 mg. No significant safety issues were identified although tolerability appeared to decline above a dose of 40 mg with 26% ...